A Blockchain With No Token Just Cleared a Drug Approval: How SUSMED Spent Six Years Moving the Verification-Cost Boundary

A World First

On September 16, 2026, SUSMED Inc., a Japanese company developing therapeutic apps and clinical trial support systems, announced that a drug whose trial was conducted using its blockchain-based clinical trial system, SUSMED SourceDataSync (SUSMED SDS), had obtained marketing approval in Japan. By the company's own research, this is the first drug approval worldwide based on a corporate clinical trial using blockchain technology. The approved product is Viatris Pharmaceuticals Japan's Wakix tablets 5mg/20mg (generic name: pitolisant hydrochloride), indicated for narcolepsy and for excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients undergoing CPAP or equivalent airway treatment. It is Japan's first oral histamine H3 receptor antagonist/inverse agonist and carries orphan drug designation for narcolepsy. The domestic Phase 3 trials were initiated by Aculys Pharma in November 2022 and January 2023; following Viatris's acquisition of Aculys in October 2025, the approval was obtained under the acquirer's name.

What the Blockchain Replaced Was Manual Reconciliation

Understanding this case requires knowing how clinical trials actually work. Regulation requires verification that source records held at medical institutions match the case report form data submitted to the pharmaceutical sponsor. Traditionally this has meant monitors travelling to sites and reconciling records by eye — a labor-intensive process. SUSMED SDS links medical data captured at the institution with case report form data using blockchain technology, replacing that reconciliation work technically. Because tampering becomes structurally detectable, the basis of trust shifts from "who checked this" to "is this structurally unalterable." No crypto asset appears. No token appears. There is not even a requirement that the ledger be public.

Six Years Spent Rewriting a Regulatory Interpretation

What deserves the most attention is not the technology but the regulatory pathway. SUSMED first ran a demonstration under the Cabinet Secretariat's regulatory sandbox, publishing the results in the international medical journal JMIR in June 2020. On that basis it applied under the gray-zone clarification scheme of the Industrial Competitiveness Enhancement Act, and on December 4, 2020, received a response from the Ministry of Health, Labour and Welfare confirming that blockchain-based data reconciliation is acceptable as a substitute for conventional work under the GCP Ministerial Ordinance. In other words, the company used these schemes not merely as a testing ground but as an instrument for rewriting the interpretation of an existing ordinance. Roughly six years after that interpretive change, the pathway reached its exit in an actual approval. Policymakers evidently regard this as significant: the press release carries comments from the Director-General of the Cabinet Office's Intellectual Property Strategy Promotion Secretariat and from a Deputy Director-General of the Ministry of Economy, Trade and Industry.

Quantified Results and the Underlying Industrial Problem

The effects are documented numerically. In a comparative study under AMED's research and development promotion network program, monitoring workload fell by 45.9%, workload at medical institutions fell by 32.0%, and the number of queries raised for data confirmation and correction fell by 46.7%. The structural context is severe. Pharmaceutical R&D expenditure has been rising at roughly 8.5% annually over the past decade, and in Japan, labor-intensive and over-specified compliance with the GCP Ministerial Ordinance has long been flagged as a problem. One report indicates that a single clinical research associate in Japan covers only about one third as many trial sites as a US counterpart. Drug lag and drug loss — where medicines available abroad remain unavailable domestically — are now framed as an economic security issue. ICH-E6(R3), the international standard for trial conduct, explicitly adopts Quality by Design, treating quality as something designed into the trial plan rather than confirmed after the fact, and this technology aligns with that direction. GAMP5 Second Edition, issued in 2022, also lists blockchain among technologies that enhance data integrity.

[Business Development Insights]

1. Blockchain's commercial case is clearest where regulation mandates third-party verification. What was replaced here was neither a payment nor a transfer, but the source-to-data reconciliation required by the GCP Ministerial Ordinance. The financial-sector equivalents are audit trail confirmation in internal audit, reconciliation of regulatory reporting data, balance verification for entrusted assets, and quality monitoring of outsourced operations. All of these consume labor because regulation demands verification, not because the labor itself creates value. It is worth reframing the opportunity search from "what assets can we tokenize" to "which regulator-mandated verification tasks can be replaced by tamper detection."
2. Japan's regulatory sandbox and gray-zone clarification schemes can function as instruments for rewriting ordinance interpretation rather than as venues for demonstration. SUSMED secured an interpretive confirmation from the health ministry in December 2020 and took six years to reach an approval. In finance, comparable pathways are plausible for questions around title transfer of tokenized assets, the handling of electronic payment instruments, and category boundaries in prepaid instrument regulation. The decisive factor is that the company did not stop at a one-off proof of concept: it accumulated independently verifiable evidence in sequence — a peer-reviewed journal publication, a comparative study under a public research program, and inclusion in an industry standard guideline. What moves a regulator is not technical novelty but third-party-verifiable evidence of substitutability.
3. The presence or absence of a token should not be a screening criterion when evaluating non-financial blockchain ventures. This case involves no crypto asset, no token, no governance token, and no necessity for a public chain. It nonetheless cleared regulatory approval as a world first and delivered a documented 45.9% reduction in monitoring workload. An application narrowed to the single property of tamper-evident recordkeeping has room to extend across traceability, digital identity, public records management, audit trails, and insurance claims — every domain where record authenticity is itself a regulatory requirement. That a Japanese company secured this world first suggests there remains substantial unexploited ground in domestic blockchain business development that carries neither price volatility nor regulatory uncertainty.

[Sources]

SUSMED Inc., "World's First: Marketing Approval Obtained for a Pharmaceutical Based on a Clinical Trial Conducted Using a Blockchain-Enabled Clinical Trial System" (September 16, 2026) https://susmed.co.jp/wp-content/uploads/2026/09/260916SUSMEDSDS.pdf NADA NEWS, "World First: Japanese Company SUSMED Achieves Drug Approval From a Blockchain-Based Clinical Trial" (September 17, 2026) https://www.nadanews.com/368501/ Viatris Pharmaceuticals Japan, "Marketing Approval Obtained for Wakix Tablets 5mg/20mg (pitolisant hydrochloride), Japan's First Histamine H3 Receptor Antagonist/Inverse Agonist" (September 16, 2026) https://prtimes.jp/main/html/rd/p/000000019.000016151.html Ministry of Health, Labour and Welfare, publication of response to a request for confirmation under the gray-zone clarification scheme (December 4, 2020) https://www.mhlw.go.jp/content/000702071.pdf SUSMED Inc., announcement of the start of Aculys Pharma's domestic Phase 3 trial of pitolisant using SUSMED's blockchain-enabled trial management system (November 2022) https://susmed.co.jp/wp-content/uploads/2022/11/aw5ser6xc7tv8y9uboni870.pdf Iyaku Tsushinsha, coverage of the Wakix marketing approval (September 17, 2026) https://iyakutsushinsha.com/2026/09/17/ Viatris, announcement on exclusive rights to pitolisant in Japan and the acquisition of Aculys Pharma in Japan and Asia-Pacific (October 2025) https://www.viatris.jp/ja-jp/newsroom/press-release/acquisition-of-aculys-pharma SUSMED Inc., SUSMED SDS product page https://www.susmed.co.jp/system/